The study examined whether patients with Brugada syndrome are sensitive to vagal stimulation or ischemia. BACKGROUND Experimental studies have suggested that a prominent transient outward current (I to )-mediated action potential notch and a subsequent loss of the action potential dome in the epicardium, but not in the endocardium, give rise to ST-segment elevation and subsequent ventricular fibrillation (VF).
In 1992, Brugada and Brugada (1) reported eight patients with a distinct electrocardiographic (ECG) pattern, consisting of right bundle branch block (RBBB) with peculiar ST-segment elevation in the right precordial leads (V 1 to V 3 ) and sudden cardiac death in the absence of any structural heart disease. Patients with these peculiar ECG abnormalities and documented ventricular fibrillation (VF) have been recognized as a subgroup (i.e., Brugada syndrome), and their clinical manifestations have been described (2) (3) (4) (5) .
Vasospastic angina is another etiology of VF in patients without identifiable structural heart disease and should be excluded to confirm the diagnosis of Brugada syndrome (6 -8) . However, coexistence of Brugada syndrome and vasospastic angina has recently been reported in a couple of case reports (9 -11) .
Recent experimental studies have suggested that a prominent transient outward current (I to )-mediated action potential notch and a subsequent loss of the action potential dome in epicardial cells, but not in endocardial cells, in the right ventricular outflow tract (RVOT), give rise to voltage gradients across the ventricular wall, resulting in STsegment elevation in the right precordial leads and subsequent VF due to the mechanism of phase 2 reentry (12, 13) . Because the maintenance of the action potential dome is determined by the balance of inward and outward currents active at the end of phase 1 of the action potential, any agents that cause an outward shift (e.g., increase in I to , increase in adenosine triphosphate-sensitive potassium current [I KATP ], decrease in calcium current [I Ca ], decrease in fast sodium current [I Na ]) can increase the magnitude of the action potential notch, leading to the ST-segment elevation and VF in patients with Brugada syndrome (14) . Therefore, we hypothesized that the increase in I KATP and/or decrease in I Ca may enhance the ST-segment elevation in the right precordial leads and induce VF in patients with Brugada syndrome, secondary to ischemia or vagomimetic action by intracoronary injection of acetylcholine (ACh) and/or ergonovine maleate (EM), especially by injection to the right coronary artery, which perfuses to the RVOT.
The present study was designed to examine this hypothesis, as well as to systematically evaluate the frequency of coexistence of Brugada syndrome and vasospastic angina.
METHODS
Patient characteristics. The study population included 27 consecutive patients affected with symptomatic Brugada syndrome who were admitted to the National Cardiovascular Center, Osaka, Japan, between 1992 and 2001. There were 26 men and 1 woman ranging in age from 21 to 63 years (mean 47 Ϯ 13). All 27 patients had episodes of syncope without any prodrome, including chest pain, or a history of aborted cardiac arrest with or without documentation of VF. In all patients, a physical examination, chest roentgenogram, laboratory values, echocardiographic study with wall motion analysis and Doppler screening, and cardiac catheterization with left and right ventriculography were performed or obtained, and no structural heart disease was found. The patients also fulfilled the following criteria (15,16): 1) spontaneously documented persistent or transient ST-segment elevation (coved or saddle-back type) in the right precordial leads V 1 to V 3 with or without some degree of RBBB; and 2) a corrected QT interval Ͻ440 ms. The control group consisted of 30 randomly selected subjects; all were men ranging in age from 38 to 75 years (mean 60 Ϯ 11) who had chest pain or chest discomfort and were suspected of having vasospastic angina. There were four patients with incomplete RBBB (QRS duration 100 to Ͻ120 ms) and two with complete RBBB (QRS duration Ն120 ms). Coronary angiography and administration of ACh and/or EM. All protocols were reviewed and approved by our Ethical Review Committee, and written, informed consent was obtained from all patients. Before coronary angiography, all drugs, including nitroglycerin and Ca 2ϩ antagonists, were discontinued for at least five half-lives of each drug. The patients were in the supine resting state and underwent coronary angiography by the Judkins technique. The left coronary angiograms in the right anterior oblique projection and the right coronary angiograms in the left anterior oblique projection were obtained in the baseline condition without injection of nitroglycerin, in a standard manner. An electrode catheter was positioned in the right ventricular apex and connected to a pacemaker for backup pacing (40 beats/min). We first injected ACh, which was diluted in 10 ml of 0.9% saline and was raised to 37°C, into the right coronary artery and then into the left coronary artery. Acetylcholine was injected over 20 s in incremental doses of 20 and 50 g within a 2-min interval. We injected EM into the right coronary artery and then into the left coronary artery in incremental doses of 10, 20, and 40 g in the same manner. The EM study was performed at least 10 min after the completion of the ACh injection. In the 27 patients with Brugada syndrome, ACh alone was injected in 6 patients, EM alone in 15 patients, and both ACh and EM in the remaining 6 patients (Patient # 22 to 27) ( Table 1 ). In the 30 control subjects, ACh alone was injected 6 patients and EM alone in 24 patients. Arterial blood pressure and the 12-lead ECG were continuously monitored before and after injection of ACh or EM. Coronary angiography was performed to observe the presence or absence of coronary spasm and whether the patients had chest discomfort, the ST segment was elevated or depressed in any leads, or the injection of the maximal dose of ACh or EM to each coronary artery was complete. If coronary spasm was induced but was not resolved spontaneously, 200 g nitroglycerin was injected into the coronary artery with spasm. Analysis of parameters. We evaluated the frequency of induction of coronary artery spasm, augmentation of STsegment elevation in the right precordial leads, and induction of VF. Coronary artery spasm was assessed at total or near-total occlusion focally. Augmentation of ST-segment elevation in leads V 1 to V 3 was defined as an increase of Ն0.1 mV in the amplitude of the ST segment 20 ms after the end of the QRS complex in lead V 1 , V 2 , or V 3 after injection of ACh or EM.
RESULTS
Clinical characteristics. Table 1 shows the clinical characteristics of the 27 patients with Brugada syndrome. In the baseline condition, 9 patients with Brugada syndrome showed a normal QRS duration, 10 patients had incomplete RBBB, and 8 patients exhibited complete RBBB. All patients had episodes of syncope, and 14 patients had a history of aborted cardiac arrest. Ventricular fibrillation was documented in 14 patients, and 4 patients had family members who died suddenly. Induction of coronary artery spasm. There was no significant organic stenosis of the right and left coronary arteries in the baseline condition in both groups. Coronary spasm was induced in 3 (11%) of the 27 patients with Brugada syndrome. Right coronary spasm (segment no. 1, 100%) was induced by the right coronary injection of ACh in one patient. Left coronary spasm was induced by the left coronary injection of ACh in one patient (segment no. 7, 90%) and by the same injection of EM in the remaining one patient (segment no. 6, 99%). In contrast, coronary spasm was induced by 4 of 6 ACh injections and by 9 of 24 EM injections in the control subjects ( Table 2) .
Augmentation of ST-segment elevation in the right precordial leads. Figure 1 shows the 12-lead ECG before and after ACh injection into the right coronary artery in a patient with Brugada syndrome. The baseline ECG shows coved or saddle-back type ST-segment elevation in leads V 1 and V 2 (Fig. 1A) . Injection of 50 g ACh augmented the ST-segment elevation in leads V 1 and V 2 , without any induction of coronary spasm (Fig. 1B) , leading to spontaneously induced VF (Fig. 1C) . Figure 2 illustrates the 12-lead ECG before and after EM injection into the right coronary artery in a control subject. In this case, injection of 40 g EM produced spasm of the right coronary artery (segment no. 2, 75%; segment no. 4, 100%), associated with ST-segment elevation in leads II, III, and aVF. However, no ST-segment elevation was observed in leads V 1 to V 3 , like that in the patient with Brugada syndrome (Fig. 2B) . In the patients with Brugada syndrome, the ST-segment elevation in leads V 1 to V 3 was augmented by 6 (55%) of 11 right coronary injections of ACh and by 5 (23%) of 22 right coronary injections of EM, and this was not associated with any induction of coronary spasm. It is noteworthy that the augmentation of ST-segment elevation localized in leads V 1 to V 3 was never induced by the left coronary injection of ACh or EM. ST-segment elevation in leads V 1 to V 3 was CA ϭ cardiac arrest; CRBBB ϭ complete right bundle branch block; ECG ϭ electrocardiographic; F ϭ female; FH ϭ family history; IRBBB ϭ incomplete right bundle branch block; M ϭ male; QRS ϭ QRS duration; QT c ϭ corrected QT interval; RBBB ϭ right bundle branch block; SR ϭ sinus rhythm; VF ϭ ventricular fibrillation; ϩ ϭ present; Ϫ ϭ absent. Noda et al. November 20, 2002 November 20, :1841 ST-Segment Elevation in Brugada Syndrome not observed by either ACh or EM injection in any of the control subjects ( Table 2) . Induction of VF. In the patients with Brugada syndrome, VF was induced by 2 (18%) of the 11 right coronary injections of ACh and by 1 (5%) of 22 right coronary injections of EM, and this was not associated with any induction of coronary spasm. Ventricular fibrillation was not induced by the left coronary injection of ACh or EM. In contrast, VF did not occur in any of the control subjects (Table 2) . Acetylcholine versus EM. The frequency of augmentation of ST-segment elevation in leads V 1 to V 3 and VF induction was evaluated in six patients with Brugada syndrome in whom both ACh and EM were used. No coronary spasm was induced by either ACh or EM in these patients. Figure  3 shows the 12-lead ECG of a patient with Brugada syndrome with injection of both ACh and EM. The baseline ECG shows coved and saddle-back type STsegment elevation in leads V 1 and V 2 (Fig. 3A) . STsegment elevation was augmented by the right coronary injection of 50 g ACh, without any induction of coronary spasm (Fig. 3B) , but not by the right coronary injection of 40 g EM (Fig. 3C ). Once again, the augmentation of ST-segment elevation in leads V 1 to V 3 was never induced by the left coronary injection of either ACh or EM.
ST-segment elevation in leads V 1 to V 3 was augmented by four of six injections of ACh, but by only one of six injections of EM. Ventricular fibrillation was induced by one of six right coronary injections of ACh (Table 3) .
DISCUSSION
Brugada syndrome and vasospastic angina. Brugada syndrome is characterized by a peculiar ST-segment elevation in leads V 1 to V 3 and an episode of VF in the absence of any structural heart disease (1-5). ST-segment elevation in any ECG lead reflecting the ischemic region and subsequent VF are also observed in patients with vasospastic angina but no structural heart disease (6 -8). Therefore, vasospastic angina must be excluded to diagnose the patient with Brugada syndrome. However, some case reports have demonstrated the combination of Brugada syndrome and vasospastic angina simultaneously (9 -11) . The present study systematically evaluated the incidence of induced coronary spasm by injections of ACh and/or EM in symptomatic patients with Brugada syndrome. The data suggest that the coexistence of vasospastic angina was not rare (11%) in symptomatic patients with Brugada syndrome. The coexistence of Brugada syndrome and vasospastic angina is clinically important, especially from a therapeutic point of view. The first line of therapy for vasospastic angina is administration of calcium antagonists or nitrates, which also have a blocking action of I Ca . The use of these agents in patients with vasospastic angina would be expected to attenuate ST- Noda et al. November 20, 2002 November 20, :1841 ST-Segment Elevation in Brugada Syndrome segment elevation in the right precordial leads and to induce VF as a result of I Ca inhibition-that is, if the patients were associated with Brugada syndrome. Therefore, the coexistence of Brugada syndrome and vasospastic angina should always be taken into account for the management of both patients with Brugada syndrome and those with vasospastic angina. Possible mechanism of augmentation of ST-segment elevation in the right precordial leads and VF by intracoronary injection of ACh and/or EM. Yan and Antzelevitch (12,13) developed an experimental model of Brugada syndrome by using arterially perfused canine right ventricular wedge preparations, and they suggested that heterogeneous repolarization across the ventricular wall of the RVOT was responsible for the ST-segment elevation and the genesis of VF in Brugada syndrome. They used several autonomic and anti-arrhythmic agents in their models and suggested that any agents that increase outward currents (I to or I KATP ) or decrease inward currents (I Ca or fast I Na ) can increase the magnitude of the action potential notch, resulting in ST-segment elevation and VF in patients with Brugada syndrome. So far, this hypothesis most likely explains the clinical manifestation, such as responses to autonomic agonists (e.g., isoproterenol, ACh) and antagonists (e.g., beta-blockers, atropine) or sodium channel blockers in patients with Brugada syndrome (16 -23) . In the present study, ST-segment elevation in leads V 1 to V 3 was augmented by the right coronary injection of ACh or EM, without any visible coronary spasm in one-third of the symptomatic patients with Brugada syndrome, but not in any of the control subjects. Of note, the left coronary injection of ACh or EM could never attenuate the STsegment elevation in leads V 1 to V 3 , even in patients with Brugada syndrome. These findings suggest that the I tomediated phase 1 notch of the epicardial cells in the RVOT was sensitive to vagal stimulation (decrease in I Ca ) produced by ACh or to mild ischemia (increase in I KATP and/or decrease in I Ca ), which was induced by EM but was not able to cause visible coronary spasm, thus resulting in the augmentation of ST-segment elevation in the right precordial leads. Augmentation of ST-segment elevation was more easily induced by the right coronary injection of ACh versus EM (55% vs. 23%). Moreover, ST-segment elevation in leads V 1 to V 3 was augmented by four of six right coronary injections of ACh, but by only one of six right coronary injections of EM in six patients with Brugada syndrome in whom both ACh and EM were used. These data indicate that suppression of I Ca by vagal stimulation with ACh played a more significant role in the mechanism of augmentation of ST-segment elevation in Brugada syndrome. Ventricular fibrillation was induced after augmentation of ST-segment elevation in the right precordial leads by three right coronary injections of ACh or EM, but not by any left coronary injections. These results indicate a correlation between prominent ST-segment elevation and subsequent VF and support the hypothesis of VF due to phase 2 reentry (24,25). 
